Ann: Appendix 3B-RAP.AX, page-19

I agree Martin. We are behind the schedule put to shareholders in last ?November. I posted this concern a couple of weeks ago. I think FDA submission, likely approval and therefore product commercialisation is at least one quarter behind schedule (depending on how quickly US trials are initiated and how quickly they can collect and collate the necessary data with the increased population size and additional resources the company has been afforded with the capital raising). These factors likely only delay the inevitable, however an updated schedule from management is overdue.